Expert Interviews

NP Theresa Stukus and NP Nelli Zafman conclude the discussion by reflecting on the resources, practice changes, and multidisciplinary strategies needed to successfully implement advances in the frontline management of metastatic triple-negative breast cancer (mTNBC).

In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.

NP Theresa Stukus and NP Nelli Zafman discuss the practical challenges patients with metastatic triple-negative breast cancer (mTNBC) may encounter during prolonged antibody-drug conjugate (ADC) therapy and the critical role of the multidisciplinary care team in supporting long-term treatment success.

NP Theresa Stukus and NP Nelli Zafman discuss practical strategies for preventing, monitoring, and managing oral and ocular toxicities in patients with metastatic triple-negative breast cancer (mTNBC) receiving antibody-drug conjugate therapy.

This closing segment follows the patient into surveillance as he and his wife worry about recurrence.

This segment addresses recognizing and managing adverse events, with nurses described as the care team's eyes on the ground.

In observation of National PA Week, Moffitt PA Mark Honor discusses the expansion of APPs and key collaboration strategies for oncology nurses.

Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.

Oncology clinicians gathered to review relapsed CLL care options, CAR T-cell trial updates, and advanced practice provider roles.

NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic triple-negative breast cancer (mTNBC) who is experiencing ongoing treatment-related toxicities while maintaining disease control on frontline therapy.

NP Theresa Stukus and NP Nelli Zafman discuss how the distinct toxicity profiles of available antibody-drug conjugates (ADCs) influence supportive care strategies for patients with metastatic triple-negative breast cancer (mTNBC).

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton regional nodal irradiation.

This segment compares the practical logistics of delivering intravesical therapies and encourages clinics to identify treatment champions among pharmacy, clinic, and provider staff.

This segment returns to the patient case to explore alternatives to repeat surgery.

At ASTRO 2026, Dr. Mishaal Munir details how nurse-led triage workflows and prompt symptom escalations improve care for breast cancer brain metastases.

ASTRO 2026 presenter Kayla Kafka-Peterson details an Adapt-Adopt-Build model to bridge global brachytherapy nursing gaps and standardize perioperative care.

At ASTRO 2026, Dr. Nitin Ohri details additive versus synergistic toxicities when combining radiation with novel systemic therapies in clinical trials.

APHON 2026 speaker Amy C. Haskamp, CNS, discusses tiered self-care tactics and boundaries to help pediatric oncology nurses navigate emotional distress and burnout.

At ASTRO 2026, DJohn Hillson details how early post-surgical radiation education within 6 weeks improves outcomes for head and neck cancer patients.

Jyoti Malhotra, MD, MPH, joins The Moonlight Shift to discuss first-in-human phase 1 lung cancer trials, healthcare access, and her work at Yale Cancer Center.

Vanderbilt APPs discuss PSA screening, multidisciplinary care, toxicity management, and genetic testing for Prostate Cancer Awareness Month.

This segment reviews standard management for newly diagnosed intermediate-risk non-muscle invasive bladder cancer.

NP Theresa Stukus and NP Nelli Zafman discuss proactive strategies for preventing and managing oral toxicities associated with antibody-drug conjugate (ADC) therapy in patients with metastatic triple-negative breast cancer (mTNBC).

NP Theresa Stukus and NP Nelli Zafman discuss practical strategies for preventing and managing neutropenia in patients with metastatic triple-negative breast cancer (mTNBC) receiving antibody-drug conjugate (ADC) therapy.

This segment introduces the patient case that anchors the program: an older retired teacher originally diagnosed with a low-grade Ta bladder tumor after noticing blood in his urine.

ANA President Jennifer Mensik Kennedy outlines systemic nurse fatigue mitigation policies, emphasizing patient safety and acuity across oncology care.

NP Theresa Stukus and NP Nelli Zafman discuss the importance of proactive patient education to support early recognition and management of gastrointestinal toxicities in metastatic triple-negative breast cancer (mTNBC).

NP Theresa Stukus and NP Nelli Zafman introduce the second clinical scenario, focusing on the evaluation and management of new-onset diarrhea in a patient with metastatic triple-negative breast cancer (mTNBC) receiving sacituzumab govitecan in combination with an immune checkpoint inhibitor.